论文部分内容阅读
对万方数据库、中国知网数据库及维普数据库所收录的1992—2012年的文献进行检索,对报道的生脉注射剂的不良反应(ADR)病例进行分类统计分析,分析生脉注射剂ADR的临床特点和发生,为其临床合理使用与安全警戒提供参考。涉及生脉注射剂的ADR病例共计1 216例,患者性别比为1∶1.01,35~65岁年龄段发生生脉注射剂ADR最多,有个人/家族过敏史的患者较易发生ADR。生脉注射剂ADR主要是在用药1 h以内发生,且累及系统-器官以全身性损害、皮肤及其附件损害为最高,主要表现为发热、过敏性休克、皮疹等。生脉注射剂发生ADR时,多存在配伍其他药品的情况。生脉注射剂ADR的发生与患者个体因素、药品成分及制剂因素、给药速度及药品配伍因素有关,通过详细了解患者基本情况、控制给药速度、避免合并用药,可以减少生脉注射剂ADR的发生。
The literature of 1992-2012 collected by Wanfang database, CNKI database and VIP database was searched, and the reported adverse reactions of Shengmai injection (ADR) were classified and analyzed. The clinical features of Shengmai injection ADR And occurred, provide reference for its clinical rational use and safety alert. A total of 1 216 ADR cases involving Shengmai injection were included, with a sex ratio of 1: 1.01. The most ADR of Shengmai injection occurred in 35-65 age group. ADR was more likely to occur in those with history of personal / family allergy. Shengmai injection ADR occurred within 1 h medication, and systemic-organ involvement systemic damage, skin and its attachments for the highest damage, mainly as fever, anaphylactic shock, rash and so on. Shengmai injection occurs when ADR, there are many cases of compatibility with other drugs. The occurrence of Shengmai injection ADR is related to the individual factors of patients, the composition and formulation of drugs, the speed of drug delivery and compatibility of drugs. By knowing the basic situation of patients, controlling the speed of drug administration and avoiding the combination of drugs, the occurrence of ADR of Shengmai injection can be reduced .